ASP2138
Sponsors
Astellas Pharma Global Development Inc., Astellas Pharma Global Development, Inc.
Conditions
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaLocally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaPancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma
Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
RecruitingNCT05365581
Start: 2022-06-07End: 2028-05-31Target: 398Updated: 2026-09-11
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
RecruitingNCT07024615
Start: 2025-10-16End: 2028-01-31Target: 25Updated: 2026-09-02
Phase 3
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
RecruitingNCT07673887
Start: 2026-07-28End: 2031-02-28Target: 570Updated: 2026-10-22
A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 plus Chemotherapy (CAPOX or mFOLFOX6) with Pembrolizumab vs Placebo plus Chemotherapy with or without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive
Not yet recruitingCTIS2025-524557-14-00
Target: 96Updated: 2026-10-23